眼周与眼表局部外用维生素A的潜在危害:系统综述与荟萃分析
该系统综述与荟萃分析检索了PubMed、Web of Science、Scopus和Cochrane Library,纳入89项研究(10,794名受试者),其中55项进入荟萃分析,评估眼表或眼周局部外用维生素A产品的眼部与眼周危害。结果显示,与对照相比,外用维生素A衍生物增加疼痛、干燥、灼烧感及任何危害的比值比,处方强度产品危害更高,非处方制剂未见显著危害增加,严重不良事件不常见且未显著增加,证据确定性为极低至低。
要点
- 外用维生素A衍生物与疼痛、干燥、灼烧感及任何危害的风险升高相关。
- 处方强度产品的危害比值比更高,非处方制剂未见显著危害增加。
- 严重不良事件不常见且未显著增加,证据确定性为极低至低。
核心结论
- 眼表或眼周局部外用维生素A产品与眼部不适及表面相关危害增加相关,尤其是处方强度制剂。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Web of Science、Scopus和Cochrane Library至2025年8月25日,遵循PRISMA指南(PROSPERO CRD42024523189)。
- 纳入评估眼表或眼周局部外用维生素A产品的人体随机与非随机研究,由两名评价者独立筛选、提取数据并评估偏倚风险。
- 89项研究(10,794名受试者)符合纳入标准,其中55项进入荟萃分析;二分类危害采用Peto固定效应比值比(OR)及95%CI合并。
主要发现
- 与对照相比,外用维生素A衍生物增加疼痛的OR=6.37。
- 与对照相比,外用维生素A衍生物增加干燥的OR=2.69。
- 与对照相比,外用维生素A衍生物增加灼烧感的OR=2.44。
- 与对照相比,外用维生素A衍生物增加任何危害的OR=1.71。
- 严重不良事件不常见且未显著增加(OR=1.21)。
关键数值与推荐
- 处方强度产品显示更高的危害比值比,非处方制剂未显示与危害增加显著相关。
- 证据确定性范围为极低至低。
临床怎么用
- 对干眼和睑板腺功能障碍管理具有重要提示,眼周使用维生素A产品需权衡处方强度制剂的眼部不适风险。
局限性
- 证据确定性范围为极低至低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Topical vitamin A derivatives (retinoids) are widely used for dermatologic and cosmetic indications and are often applied to the face and periorbital region. Although vitamin A is essential for epithelial integrity and tear film homeostasis, concerns exist regarding potential adverse effects on the ocular surface and meibomian glands. This systematic review and meta-analysis evaluated ophthalmic and periorbital harms associated with topical vitamin A products. METHODS: PubMed, Web of Science, Scopus, and the Cochrane Library were searched from inception to August 25, 2025, following PRISMA guidelines (PROSPERO CRD42024523189). Randomized and nonrandomized human studies evaluating topical vitamin A products applied to the ocular surface or periorbital region were included. Studies were independently screened, data were extracted, and risk of bias was assessed by two reviewers. Dichotomous harms were pooled using Peto fixed-effects odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: Eighty-nine studies (10,794 participants) met inclusion criteria; 55 were included in meta-analysis. Compared with controls, topical vitamin A derivatives increased odds of pain (OR = 6.37), dryness (OR = 2.69), burning (OR = 2.44), and any harm (OR = 1.71). Serious adverse events were uncommon and not significantly increased (OR = 1.21). Prescription-strength products showed higher odds of harm, and non-prescription formulations were not significantly associated with increased harms. Evidence certainty ranged from very low to low. CONCLUSIONS: Topical vitamin A products applied to the ocular or periorbital region are associated with increased ocular discomfort and surface-related harms, particularly with prescription-strength formulations, with important implications for dry eye and meibomian gland dysfunction management.
引用
- Abbott KS, Kruoch Z, Pucker A, et al. Potential Harms of Ocular and Periorbital Topical Vitamin A Application: A Systematic Review and Meta-Analysis. Invest Ophthalmol Vis Sci. 2026. PMID: 42708560. doi:10.1167/iovs.67.11.11
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。